You are here: Business & Industry Strategy

Strategy

Focusing our efforts and resources to ensure we deliver our purpose.

E-mail Print PDF

In response to the external environment, and as we announced at our Investor Day in March 2013, updated in May this year, we have made a clear set of strategic choices.

UCB clinical trials policy

E-mail Print PDF

UCB is committed to providing the opportunity to patients to make informed decisions about participating in clinical trials.

Lilly's Humalog® 200 Units/ML KwikPen® Now Available In U.S. Pharmacies

E-mail Print PDF

First and only concentrated mealtime insulin analog may help people with diabetes fit their treatment into their daily lives.Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), the first and only concentrated mealtime insulin analog in the U.S., is now available .

Last Updated on Friday, 25 September 2015 05:56

OncoMed Pharmaceuticals and Bayer HealthCare Expand Cancer Stem Cell Collaboration with Clinical Manufacturing Agreement

E-mail Print PDF

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics targeting cancer stem cells, today announced it has expanded its collaboration with Bayer HealthCare. Bayer’s U.S. affiliate will manufacture clinical supplies of a second Wnt inhibitor in the alliance.

Last Updated on Wednesday, 25 July 2012 07:19

Merck Wins First FOSAMAX] (alendronate sodium) State Court Trial

E-mail Print PDF

Merck & Co., Inc. said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

Medicis and Anacor Enter Into Research and Development Collaboration for the Treatment of Acne

E-mail Print PDF

Medicis Pharmaceutical Corporation and Anacor Pharmaceuticals, Inc. announced that the two companies have entered into a research and development agreement to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne.

GSK announces the sale of its entire shareholding in Quest Diagnostics

E-mail Print PDF

GlaxoSmithKline plc announces that it has sold its entire holding of 30,755,151 shares of common stock in Quest Diagnostics Inc. (“Quest”).  The sale comprised a secondary public offering by GSK (the “Offering”) and an accompanying repurchase of shares by Quest (the “Repurchase”).  GSK originally acquired the shareholding as partial consideration for the sale of its clinical laboratories business in 1999 and has since gradually reduced its stake in stages.

Merck and Parexel form Strategic Allicance focused on Clinical Development

E-mail Print PDF

Merck known outside the United States and Canada as MSD and PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that they have entered into an alliance by which PAREXEL will provide strategic access to global clinical development services for designated biosimilar candidates to Merck BioVentures.  Merck BioVentures, a division of Merck, is focused on the delivery of high quality biosimilars to the patients that need them.

Caraco Pharmaceutical Laboratories, Ltd. Provides Update on Remediation Activities

E-mail Print PDF

Caraco Pharmaceutical Laboratories, Ltd. announced that based on remediation efforts to date, it does not expect to commence the manufacture and distribution of products from its Detroit facility by the end of Caraco's Fiscal Year 2011, ending March 31, 2011. The Company had previously disclosed its belief that two products would commence manufacture in the Detroit facility prior to the end of Fiscal 2011.

EpiTherapeutics and Abbott Enter into Oncology Collaboration on Epigenetic Targets

E-mail Print PDF

Abbott Park, Illinois and Copenhagen, Denmark — EpiTherapeutics and Abbott announced a collaboration agreement to develop new anti-cancer drugs by making small-molecule inhibitors against selected epigenetic oncology targets. Under the terms of the agreement EpiTherapeutics receives an up-front payment and will receive funding of research activities at EpiTherapeutics. Further, EpiTherapeutics is eligible, under certain conditions, to receive milestone payments as well as potential royalties on future revenues. Additional financial details were not disclosed.

Page 1 of 3

  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  Next 
  •  End 
  • »